Compare Quest Diagnostics Inc (DGX) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hasbro, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Hasbro, Inc. trades at $78.85 (market cap $11.10B). The key difference: Quest Diagnostics Inc is far larger — about 2.1× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| DGX | HAS | |
|---|---|---|
Market Cap | $22.80B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $105.88 |
52-Week Low | $166.42 | $70.95 |
Enterprise Value | $28.82B | $13.37B |
Dividend Yield | 1.67% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Hasbro (HAS) trades at $79.53, showing modest daily gains but facing bearish technical signals. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B, with profitability metrics showing strain. Recent earnings beats provide some optimism, while analyst consensus remains positive with a $104 price target representing 31% upside potential from current levels.
Investment outlook balances strong analyst support against fundamental challenges. The stock offers significant upside if management can improve profitability, but faces headwinds from negative margins and high debt levels. Key catalysts include Q2 2026 earnings on July 21 and execution of the company's 'aging up' strategy targeting adult consumers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
